Methotrexate-related lymphoproliferative disorders in the liver: Case presentation and mini-review

Table 1 Laboratory data on admission of a patient with methotrexate-associated lymphoproliferative liver tumors

Item	Data	Item	Data	Item	Data
White blood cells	13900 /μL	Total protein	7.1 g/dL	Sodium	134 mEq/L
Neutrophils	82.9%	Albumin	3.6 g/dL	Potassium	4.3 mEq/L
Lymphocytes	8.6%	AST	316 IU/L	Chloride	97 mEq/L
Monocytes	8.4%	ALT	370 IU/L	CRP	18.74 mg/dL
Eosinophils	0%	ALP	2006 IU/L	CEA	1.5 ng/mL
Basophils	0.1%	LDH	2844 IU/L	CA19-9	4.0 U/mL
Red blood cells	389 × 104 /μL	γ-GTP	1300 IU/L	AFP	2.0 ng/mL
Hemoglobin	12.6 g/dL	T. Bil	2.51 mg/dL	PIVKA-II	16 mAU/mL
Platelet count	25.8 × 104 /μL	D. Bil	0.82 mg/dL	sIL2R	2120 U/mL
PT	84.7%	BUN	25.6 mg/dL
APTT	30.4 s	Creatinine	0.63 mg/dL

PT: Prothrombin time activity; APTT: Activated partial thromboplastin time; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; γ-GTP: γ-glutamyltransferase; T. Bil: Total bilirubin; D. Bil: Direct bilirubin; BUN: Blood urea nitrogen; CRP: C-reactive protein; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; AFP: α-fetoprotein; PIVKA-II: Protein induced by vitamin K absence or antagonist II; sIL2R: Soluble interleukin-2 receptor.